AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. VOR
  4. [144] Vor Biopharma Inc. SEC Filing

[144] Vor Biopharma Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Vor Biopharma Inc. (VOR) filed a Form 144 indicating an intention to sell restricted shares under Rule 144.

  • Securities for sale: 29,432 common shares.
  • Proposed broker: Morgan Stanley Smith Barney LLC, 1 New York Plaza, NY.
  • Proposed sale date: 08 / 04 / 2025 on NASDAQ.
  • Aggregate market value of planned sale: $61,589.40.
  • Shares outstanding: 124,959,520; proposed sale equals roughly 0.02 % of total.
  • Acquisition details: Shares obtained on 08 / 04 / 2025 via exercise for cash.

No prior sales in the last three months were reported, and the filer certifies no undisclosed material adverse information. The filing is routine, signals limited insider liquidity, and does not materially alter VOR鈥檚 capital structure.

Vor Biopharma Inc. (VOR) ha presentato un Modulo 144 indicando l鈥檌ntenzione di vendere azioni ristrette ai sensi della Regola 144.

  • Titoli in vendita: 29.432 azioni ordinarie.
  • Broker proposto: Morgan Stanley Smith Barney LLC, 1 New York Plaza, NY.
  • Data di vendita proposta: 04/08/2025 sul NASDAQ.
  • Valore di mercato aggregato della vendita prevista: 61.589,40 $.
  • Azioni in circolazione: 124.959.520; la vendita proposta rappresenta circa lo 0,02% del totale.
  • Dettagli sull鈥檃cquisizione: Azioni ottenute il 04/08/2025 tramite esercizio a pagamento.

Non sono state segnalate vendite precedenti negli ultimi tre mesi e il dichiarante certifica l鈥檃ssenza di informazioni materiali sfavorevoli non divulgate. La presentazione 猫 di routine, indica una liquidit脿 insider limitata e non modifica sostanzialmente la struttura del capitale di VOR.

Vor Biopharma Inc. (VOR) present贸 un Formulario 144 indicando la intenci贸n de vender acciones restringidas bajo la Regla 144.

  • Valores a la venta: 29,432 acciones comunes.
  • Corredor propuesto: Morgan Stanley Smith Barney LLC, 1 New York Plaza, NY.
  • Fecha propuesta de venta: 04/08/2025 en NASDAQ.
  • Valor de mercado agregado de la venta planificada: $61,589.40.
  • Acciones en circulaci贸n: 124,959,520; la venta propuesta representa aproximadamente el 0.02% del total.
  • Detalles de adquisici贸n: Acciones obtenidas el 04/08/2025 mediante ejercicio en efectivo.

No se reportaron ventas previas en los 煤ltimos tres meses y el declarante certifica que no hay informaci贸n material adversa no divulgada. La presentaci贸n es rutinaria, indica liquidez limitada de insiders y no altera materialmente la estructura de capital de VOR.

Vor Biopharma Inc. (VOR)電� 攴滌箼 144鞐� 霐半澕 鞝滍暅 欤检嫕鞚� 韺愲Г頃� 鞚橃偓毳� 雮橅儉雮措姅 鞏戩嫕 144毳� 鞝滌稖頄堨姷雼堧嫟.

  • 韺愲Г頃� 歃濌秾: 氤错喌欤� 29,432欤�.
  • 鞝滌晥霅� 欷戧皽鞚�: Morgan Stanley Smith Barney LLC, 1 New York Plaza, NY.
  • 鞓堨爼 韺愲Г鞚�: 2025雲� 8鞗� 4鞚�, NASDAQ.
  • 鞓堨爼 韺愲Г鞚� 齑� 鞁滌灔 臧�旃�: $61,589.40.
  • 氚滍枆 欤检嫕 靾�: 124,959,520欤�; 鞝滌晥霅� 韺愲Г電� 鞝勳泊鞚� 鞎� 0.02%鞐� 頃措嫻.
  • 旆摑 靹鸽秬靷暛: 2025雲� 8鞗� 4鞚� 順勱笀 頄夓偓搿� 旆摑頃� 欤检嫕.

斓滉芳 3臧滌洈 雮� 鞚挫爠 韺愲Г電� 氤搓碃霅橃 鞎婌晿鞙茧┌, 鞝滌稖鞛愲姅 氙戈车臧滊悳 欷戩殧頃� 攵�鞝曥爜 鞝曤炒臧� 鞐嗢潓鞚� 鞚胳頃╇媹雼�. 鞚� 鞝滌稖鞚� 鞚检儊鞝侅澑 鞝堨皑搿�, 雮措秬鞛� 鞙犽彊靹膘澊 鞝滍暅鞝侅瀯鞚� 雮橅儉雮措┌ VOR鞚� 鞛愲掣 甑“鞐� 鞁れ鞝侅澑 氤�頇旊ゼ 欤检 鞎婌姷雼堧嫟.

Vor Biopharma Inc. (VOR) a d茅pos茅 un formulaire 144 indiquant son intention de vendre des actions restreintes conform茅ment 脿 la r猫gle 144.

  • Titres 脿 vendre : 29 432 actions ordinaires.
  • Interm茅diaire propos茅 : Morgan Stanley Smith Barney LLC, 1 New York Plaza, NY.
  • Date de vente propos茅e : 04/08/2025 sur NASDAQ.
  • Valeur marchande totale de la vente pr茅vue : 61 589,40 $.
  • Actions en circulation : 124 959 520 ; la vente propos茅e repr茅sente environ 0,02 % du total.
  • D茅tails de l鈥檃cquisition : Actions obtenues le 04/08/2025 via un exercice au comptant.

Aucune vente ant茅rieure n鈥檃 茅t茅 signal茅e au cours des trois derniers mois, et le d茅clarant certifie qu鈥檃ucune information d茅favorable importante non divulgu茅e n鈥檈st en sa possession. Le d茅p么t est de routine, indique une liquidit茅 limit茅e des initi茅s et ne modifie pas de mani猫re significative la structure du capital de VOR.

Vor Biopharma Inc. (VOR) hat ein Formular 144 eingereicht, das die Absicht anzeigt, eingeschr盲nkte Aktien gem盲脽 Regel 144 zu verkaufen.

  • Zum Verkauf stehende Wertpapiere: 29.432 Stammaktien.
  • Vorgeschlagener Broker: Morgan Stanley Smith Barney LLC, 1 New York Plaza, NY.
  • Vorgeschlagenes Verkaufsdatum: 04.08.2025 an der NASDAQ.
  • Gesamtmarktwert des geplanten Verkaufs: 61.589,40 $.
  • Ausstehende Aktien: 124.959.520; der geplante Verkauf entspricht etwa 0,02 % des Gesamtbestands.
  • Erwerbsdetails: Aktien am 04.08.2025 durch Baraus眉bung erworben.

In den letzten drei Monaten wurden keine vorherigen Verk盲ufe gemeldet, und der Einreicher best盲tigt, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen. Die Einreichung ist routinem盲脽ig, signalisiert begrenzte Insider-Liquidit盲t und ver盲ndert die Kapitalstruktur von VOR nicht wesentlich.

Positive
  • None.
Negative
  • Insider intends to sell shares, which can be perceived negatively, albeit the volume is minimal.

Insights

TL;DR: Small Rule 144 sale (0.02 % float) 鈥� immaterial to valuation, neutral signal.

The notice covers 29,432 shares worth 鈮�$62k against a 125 m share base. Such size is negligible for liquidity or ownership structure and reflects ordinary portfolio diversification or option exercise. Absence of past-quarter sales and disclosure that no material non-public information is held reduces governance risk. Investors should monitor subsequent Form 4 filings for exact execution prices but, in isolation, this event is neutral to VOR鈥檚 investment thesis.

TL;DR: Routine insider trade notice; no red flags or strategic implications detected.

Form 144 merely grants the right to sell; it is not a commitment. The filer鈥檚 representation of no undisclosed adverse information complies with Rule 144 and 10b5-1 standards. Given the limited dollar amount, there is minimal reputational or signaling risk. I classify the impact as not impactful; however, continual monitoring of cumulative insider activity remains best practice for governance oversight.

Vor Biopharma Inc. (VOR) ha presentato un Modulo 144 indicando l鈥檌ntenzione di vendere azioni ristrette ai sensi della Regola 144.

  • Titoli in vendita: 29.432 azioni ordinarie.
  • Broker proposto: Morgan Stanley Smith Barney LLC, 1 New York Plaza, NY.
  • Data di vendita proposta: 04/08/2025 sul NASDAQ.
  • Valore di mercato aggregato della vendita prevista: 61.589,40 $.
  • Azioni in circolazione: 124.959.520; la vendita proposta rappresenta circa lo 0,02% del totale.
  • Dettagli sull鈥檃cquisizione: Azioni ottenute il 04/08/2025 tramite esercizio a pagamento.

Non sono state segnalate vendite precedenti negli ultimi tre mesi e il dichiarante certifica l鈥檃ssenza di informazioni materiali sfavorevoli non divulgate. La presentazione 猫 di routine, indica una liquidit脿 insider limitata e non modifica sostanzialmente la struttura del capitale di VOR.

Vor Biopharma Inc. (VOR) present贸 un Formulario 144 indicando la intenci贸n de vender acciones restringidas bajo la Regla 144.

  • Valores a la venta: 29,432 acciones comunes.
  • Corredor propuesto: Morgan Stanley Smith Barney LLC, 1 New York Plaza, NY.
  • Fecha propuesta de venta: 04/08/2025 en NASDAQ.
  • Valor de mercado agregado de la venta planificada: $61,589.40.
  • Acciones en circulaci贸n: 124,959,520; la venta propuesta representa aproximadamente el 0.02% del total.
  • Detalles de adquisici贸n: Acciones obtenidas el 04/08/2025 mediante ejercicio en efectivo.

No se reportaron ventas previas en los 煤ltimos tres meses y el declarante certifica que no hay informaci贸n material adversa no divulgada. La presentaci贸n es rutinaria, indica liquidez limitada de insiders y no altera materialmente la estructura de capital de VOR.

Vor Biopharma Inc. (VOR)電� 攴滌箼 144鞐� 霐半澕 鞝滍暅 欤检嫕鞚� 韺愲Г頃� 鞚橃偓毳� 雮橅儉雮措姅 鞏戩嫕 144毳� 鞝滌稖頄堨姷雼堧嫟.

  • 韺愲Г頃� 歃濌秾: 氤错喌欤� 29,432欤�.
  • 鞝滌晥霅� 欷戧皽鞚�: Morgan Stanley Smith Barney LLC, 1 New York Plaza, NY.
  • 鞓堨爼 韺愲Г鞚�: 2025雲� 8鞗� 4鞚�, NASDAQ.
  • 鞓堨爼 韺愲Г鞚� 齑� 鞁滌灔 臧�旃�: $61,589.40.
  • 氚滍枆 欤检嫕 靾�: 124,959,520欤�; 鞝滌晥霅� 韺愲Г電� 鞝勳泊鞚� 鞎� 0.02%鞐� 頃措嫻.
  • 旆摑 靹鸽秬靷暛: 2025雲� 8鞗� 4鞚� 順勱笀 頄夓偓搿� 旆摑頃� 欤检嫕.

斓滉芳 3臧滌洈 雮� 鞚挫爠 韺愲Г電� 氤搓碃霅橃 鞎婌晿鞙茧┌, 鞝滌稖鞛愲姅 氙戈车臧滊悳 欷戩殧頃� 攵�鞝曥爜 鞝曤炒臧� 鞐嗢潓鞚� 鞚胳頃╇媹雼�. 鞚� 鞝滌稖鞚� 鞚检儊鞝侅澑 鞝堨皑搿�, 雮措秬鞛� 鞙犽彊靹膘澊 鞝滍暅鞝侅瀯鞚� 雮橅儉雮措┌ VOR鞚� 鞛愲掣 甑“鞐� 鞁れ鞝侅澑 氤�頇旊ゼ 欤检 鞎婌姷雼堧嫟.

Vor Biopharma Inc. (VOR) a d茅pos茅 un formulaire 144 indiquant son intention de vendre des actions restreintes conform茅ment 脿 la r猫gle 144.

  • Titres 脿 vendre : 29 432 actions ordinaires.
  • Interm茅diaire propos茅 : Morgan Stanley Smith Barney LLC, 1 New York Plaza, NY.
  • Date de vente propos茅e : 04/08/2025 sur NASDAQ.
  • Valeur marchande totale de la vente pr茅vue : 61 589,40 $.
  • Actions en circulation : 124 959 520 ; la vente propos茅e repr茅sente environ 0,02 % du total.
  • D茅tails de l鈥檃cquisition : Actions obtenues le 04/08/2025 via un exercice au comptant.

Aucune vente ant茅rieure n鈥檃 茅t茅 signal茅e au cours des trois derniers mois, et le d茅clarant certifie qu鈥檃ucune information d茅favorable importante non divulgu茅e n鈥檈st en sa possession. Le d茅p么t est de routine, indique une liquidit茅 limit茅e des initi茅s et ne modifie pas de mani猫re significative la structure du capital de VOR.

Vor Biopharma Inc. (VOR) hat ein Formular 144 eingereicht, das die Absicht anzeigt, eingeschr盲nkte Aktien gem盲脽 Regel 144 zu verkaufen.

  • Zum Verkauf stehende Wertpapiere: 29.432 Stammaktien.
  • Vorgeschlagener Broker: Morgan Stanley Smith Barney LLC, 1 New York Plaza, NY.
  • Vorgeschlagenes Verkaufsdatum: 04.08.2025 an der NASDAQ.
  • Gesamtmarktwert des geplanten Verkaufs: 61.589,40 $.
  • Ausstehende Aktien: 124.959.520; der geplante Verkauf entspricht etwa 0,02 % des Gesamtbestands.
  • Erwerbsdetails: Aktien am 04.08.2025 durch Baraus眉bung erworben.

In den letzten drei Monaten wurden keine vorherigen Verk盲ufe gemeldet, und der Einreicher best盲tigt, dass keine nicht offengelegten wesentlichen nachteiligen Informationen vorliegen. Die Einreichung ist routinem盲脽ig, signalisiert begrenzte Insider-Liquidit盲t und ver盲ndert die Kapitalstruktur von VOR nicht wesentlich.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source:

FAQ

How many VOR shares are being registered for sale in this Form 144?

The notice covers 29,432 common shares of Vor Biopharma Inc.

What is the total market value of the proposed VOR share sale?

The aggregate market value is $61,589.40 based on the filing.

When is the anticipated sale date for the VOR shares?

The filer lists 08/04/2025 as the approximate sale date.

How does the planned sale compare to Vor Biopharma鈥檚 shares outstanding?

The 29,432 shares represent roughly 0.02 % of the 124,959,520 shares outstanding.

Which broker will handle the proposed sale of VOR shares?

Morgan Stanley Smith Barney LLC, Executive Financial Services, New York, is named as broker.
Stock VOR logo
Vor Biopharma Inc.

NASDAQ:VOR

VOR Rankings

#3921 Ranked by Market Cap
N/A Ranked by Dividends

VOR Latest News

Aug 13, 2025
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sj枚gren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor
Aug 4, 2025
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
Jul 21, 2025
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors
Jul 18, 2025
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jul 17, 2025
Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer

VOR Latest SEC Filings

Aug 12, 2025
[10-Q] Vor Biopharma Inc. Quarterly Earnings Report
Aug 11, 2025
[144] Vor Biopharma Inc. SEC Filing
Aug 8, 2025
[DEF 14A] Vor Biopharma Inc. Definitive Proxy Statement
Aug 6, 2025
[SCHEDULE 13G/A] Vor Biopharma Inc. SEC Filing
Jul 30, 2025
[Form 4] Vor Biopharma Inc. Insider Trading Activity

VOR Stock Data

248.67M
70.29M
43.75%
46.53%
11.51%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
CAMBRIDGE